Table 5.
Overall Survival | |||||||||||
Crude | |||||||||||
N = 88 | (%) | median (months) | (95% CI) | 1-year OS (%) | (95% CI) | 2-year OS (%) | (95% CI) | HR | (95% CI) | p-value | |
CR/PR | 16 | (18) | NR | 94 | (63–99) | 94 | (63–99) | 0.02 | (0.003–0.15) | <0.001 | |
SD | 26 | (30) | 11.1 | (8.6–20.7) | 46 | (27–64) | 27 | (12–45) | 0.37 | (0.21–0.65) | 0.001 |
PD | 46 | (52) | 6.4 | (3.3–9.0) | 17 | (8–30) | 0 | (NA-NA) | 1 (reference) | ||
Progression-Free Survival | |||||||||||
Crude | |||||||||||
N = 88 | (%) | median (months) | (95% CI) | 1-year PFS (%) | (95% CI) | 2-year PFS (%) | (95% CI) | HR | (95% CI) | p-value | |
CR/PR | 16 | (18) | NR | (22.1-NA) | 88 | (59–97) | 78 | (44–93) | 0.02 | (0.005–0.06) | <0.001 |
SD | 26 | (30) | 7.0 | (4.3–12.4) | 34 | (16–52) | 17 | (5–34) | 0.10 | (0.05–0.22) | <0.001 |
PD | 46 | (52) | 1.5 | (1.1–2.5) | NA | (NA-NA) | 0 | (NA-NA) | 1 (reference) |
Abbreviations: NA, not available; NR, not reached.